免疫原
Synthesized peptide derived from part region of human protein AA range: 1-50
特异性
DLRB1 Polyclonal Antibody detects endogenous levels of protein.
来源
Polyclonal, Rabbit,IgG
组成(Formulation)
Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
稀释比例
WB 1:500-2000 ELISA 1:5000-20000
纯化工艺(Immunogen)
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
背景(Background)
This gene is a member of the roadblock dynein light chain family. The encoded cytoplasmic protein is capable of binding intermediate chain proteins, interacts with transforming growth factor-beta, and has been implicated in the regulation of actin modulating proteins. Upregulation of this gene has been associated with hepatocellular carcinomas, suggesting that this gene may be involved in tumor progression. Alternative splicing results in multiple transcript variants. Pseudogenes of this gene have been defined on chromosomes 12 and 18. [provided by RefSeq, Aug 2013],
功能
alternative products:Additional isoforms seem to exist,function:May be involved in assembly and motor function of dynein, which plays a central role in cell division and intracellular transport.,miscellaneous:Isoform 1 expression is up-regulated in 64% hepatocellular carcinoma (HCC) patients.,similarity:Belongs to the GAMAD family.,subunit:Homodimer.,tissue specificity:High expression in heart, liver, brain and pancreas; moderate in placenta, skeletal muscle and kidney; low in lung, prostate, testis, small intestine and colon.,
基因名称(Gene Name)
DYNLRB1 BITH DNCL2A DNLC2A ROBLD1 HSPC162
蛋白名称
Dynein light chain roadblock-type 1 (Bithoraxoid-like protein) (BLP) (Dynein light chain 2A, cytoplasmic) (Dynein-associated protein Km23) (Roadblock domain-containing protein 1)
Fields
>>Salmonella infection
细胞定位
Cytoplasm, cytoskeleton.
组织表达
High expression in heart, liver, brain and pancreas; moderate in placenta, skeletal muscle and kidney; low in lung, prostate, testis, small intestine and colon. Isoform 1 expression is up-regulated in 64% hepatocellular carcinoma (HCC) patients.